Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

Investor Overview

Webcast ImageWebcast
vTv Therapeutics Inc. KOL Breakfast (Replay)
11/16/17 at 8:30 a.m. ET
vTv Therapeutics Inc. KOL Breakfast
Thursday, November 16, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Presentations
DateTitle
09/07/17
Download Documentation Investor Presentation
07/27/16
Download Documentation AAIC 2016 Azeliragon Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
11/13/17vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 13, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November 16, 2017 from 8:00 am to 10:00 am ET. The event will feature two speakers, each with extensive experience in the clinical development in Alzheimer... 
Printer Friendly Version
11/08/17vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
As Part of Industry Partnership with JDRF HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 8, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study is designed to evaluate whether TTP399 is well tolerated when administered as an add-on to insulin the... 
Printer Friendly Version
11/01/17vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 1, 2017-- vTv Therapeutics Inc. (vTv Therapeutics) (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017. “We’ve made significant progress in the third quarter of 2017 across our strategic initiatives, and we attribute that to our ongoing development of innovative therapies, particularly in the areas of Alzheimer’s and ... 
Printer Friendly Version
10/30/17vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
-- Azeliragon is the only receptor for advanced glycation endproducts (RAGE) antagonist in clinical development for Alzheimer’s disease -- HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 30, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT), today announced that the Company will present three posters on clinical trials related to its lead investigational Alzheimer’s program candidate, azeliragon, at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference ... 
Printer Friendly Version
Webcasts
DateTitle
11/16/17
Download Documentation vTv Therapeutics Inc. KOL Breakfast
Get help downloading or viewing the above file types
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.